Abstract
Valved conduits often correct the blood flow of congenital heart disease by connecting the right ventricle to the pulmonary artery (RV-PA). The homograft valved conduit was invented in the 1960s, but its wide application is limited due to the lack of effective sterilization and preservation methods. Modern cryopreservation prolongs the preservation time of homograft valved conduit, which makes it become the most important treatment at present, and is widely used in Ross and other operations. However, homograft valved conduit has limited biocompatibility and durability and lacks any additional growth capacity. Therefore, decellularized valved conduit has been proposed as an effective improved method, which can reduce immune response and calcification, and has potential growth ability. In addition, as a possible substitute, commercial xenograft valved conduit has certain advantages in clinical application, and tissue engineering artificial valved conduit needs to be further studied.
Highlights
In tetralogy of Fallot combined with pulmonary atresia or other types of severe cardiac malformations, the use of valved conduits to reconstruct the ventricular outflow tract is required to restore normal hemodynamics
From the 1960s, when valved conduits were first used, improvements in preservation methods have greatly expanded the use of homograft valved conduits in clinical practice
Tricuspid natural aortic valve, and higher preoperative gradients were significantly associated with higher autograft gradients
Summary
In tetralogy of Fallot combined with pulmonary atresia or other types of severe cardiac malformations, the use of valved conduits to reconstruct the ventricular outflow tract is required to restore normal hemodynamics. From the 1960s, when valved conduits were first used, improvements in preservation methods have greatly expanded the use of homograft valved conduits in clinical practice. This technology has been rapidly developed at present. The basic research, clinical trials, and follow-up reports on valved conduits have been published continuously, opening up new avenues for the treatment of complex precordial and vascular disease. This article reviews the advances in homograft valved conduit and its clinical applications and provides an outlook on this field
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
